Helix Biopharma Corp. (TSE:HBP) has released an update.
Helix BioPharma Corp., a Toronto-based clinical-stage biopharmaceutical company, has successfully completed a private placement of common shares, raising CAD$1.9 million to bolster working capital. The offering involved the sale of over 12 million shares at $0.15 each, subject to a four-month hold period and TSX final approval. The funds will advance the company’s innovative immune-oncology therapies and proprietary DOS47 platform.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
